Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction

BACKGROUND: Trametinib is an oral MEK 1/2 inhibitor, with a single agent recommended phase 2 dose (RP2D) of 2 mg daily (QD). This study was designed to evaluate RP2D, maximum tolerated dose (MTD), and pharmacokinetic (PK) profile of trametinib in patients with advanced solid tumors who had various d...

Descripción completa

Detalles Bibliográficos
Autores principales: Voon, Pei Jye, Chen, Eric X., Chen, Helen X., Lockhart, Albert C., Sahebjam, Solmaz, Kelly, Karen, Vaishampayan, Ulka N., Subbiah, Vivek, Razak, Albiruni R., Renouf, Daniel J., Hotte, Sebastien J., Singh, Arti, Bedard, Philippe L., Hansen, Aaron R., Ivy, S. Percy, Wang, Lisa, Stayner, Lee-Anne, Siu, Lillian L., Spreafico, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819907/
https://www.ncbi.nlm.nih.gov/pubmed/35130943
http://dx.doi.org/10.1186/s13046-021-02236-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819907/
https://www.ncbi.nlm.nih.gov/pubmed/35130943
http://dx.doi.org/10.1186/s13046-021-02236-7

Ejemplares similares